MIHPC's report highlights major disparities in drug prices across Michigan hospitals, showcasing the urgent need for transparency and accountability.

The Michigan Health Purchasers Coalition (MIHPC) has released three research reports highlighting perceived disparities in ...

Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis.

Bengaluru: Biocon Biologics Limited has announced that the Government of Malaysia has agreed to extend the current contract ...

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...

and Stimufend® (pegfilgrastim-fpgk). Fresenius Kabi’s growing pipeline of autoimmune and oncology biosimilars has several molecules in early and late-stage development. Otulfi (ustekinumab-aauz ...

Last month, Sandoz revealed that the FDA had rejected its biosimilar of Amgen's Neulasta (pegfilgrastim ... Mehul Desai, VP of medical affairs at Enable Injections, sat down with pharmaphorum ...

A Michigan coalition urges patients and employers to compare hospital drug prices as new data reveals steep and unexplained ...

and Stimufend ® (pegfilgrastim-fpgk). Fresenius Kabi’s growing pipeline of autoimmune and oncology biosimilars has several molecules in early and late-stage development. Otulfi (ustekinumab-aauz) is ...

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...